查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1565654

艰难梭菌感染治疗市场，按类型、给药途径、最终用户、国家和地区 - 2024-2032 年行业分析、市场规模、市场份额和预测

Clostridium Difficile Infection Treatment Market, By Type, By Route of Administration, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 303 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告要点

2023年，艰难梭菌感染治疗市场规模为8.969亿美元，2024年至2032年复合年增长率为7.90%。

艰难梭菌感染治疗市场-市场动态

院内感染发病率上升推动了对艰难梭菌感染治疗解决方案的需求

院内感染 (HAIs) 盛行率的不断上升，加剧了对艰难梭菌感染有效治疗的需求。根据美国疾病管制与预防中心 (CDC) 的数据，医院感染每天影响约三分之一的医院患者，其中艰难梭菌是最常见的罪魁祸首之一。 2020 年，CDC 报告称，光是在美国，艰难梭菌就导致近 223,900 例住院患者感染，造成 12,800 多人死亡。医疗机构为减少医院感染所做的努力以及严格的感染控制措施正在推动更先进、更有针对性的治疗方法的采用。由于人们对抗生素抗药性的持续担忧，作为对抗这些感染的更广泛策略的一部分，粪便微生物移植 (FMT) 等替代疗法的发展势头强劲。

艰难梭菌感染治疗市场 - 关键见解

根据我们的研究分析师分享的分析，预计全球市场在预测期内（2024-2032 年）每年将以 7.90% 左右的复合年增长率成长

根据类型细分，预计抗生素将在 2023 年显示最大的市场份额

根据给药途径细分，2023年口服是领先类型

按地区划分，北美是 2023 年的主要收入来源

艰难梭菌感染治疗市场-細項分析：

全球艰难梭菌感染治疗市场根据类型、给药途径、最终用户和地区进行细分。

市场依类型分为四大类：抗生素、益生菌、粪便微生物移植（FMT）和单株抗体。抗生素因其广泛使用而在艰难梭菌感染治疗市场中占据主导地位，其次是粪便微生物移植（FMT）作为替代疗法的发展势头。单株抗体不断涌现，而益生菌作为支持性治疗越来越受到关注。

根据给药途径，市场分为三类：口服、静脉注射和直肠给药。由于简单且患者依从性良好，口服给药是艰难梭菌治疗中最常见的，其次是静脉给药，用于治疗严重病例。直肠给药较不常见，但用于粪便微生物移植 (FMT) 等标靶治疗。

艰难梭菌感染治疗市场 - 地理洞察

艰难梭菌感染治疗市场显示出显着的地区差异，其中北美由于高感染率和强大的医疗基础设施而处于领先地位。 CDC 估计，艰难梭菌每年在美国造成近 12,800 人死亡，使其成为公共卫生措施的重点对象。欧洲紧随其后，欧洲疾病预防和控制中心（ECDC）实施了严格的感染控制措施，包括强制报告医院感染，这刺激了市场成长。亚太地区的意识不断提高，诊断能力不断提高，特别是在日本和中国等国家。 2021年，日本厚生省发起了减少抗菌药物抗药性的倡议，直接影响了对CDI治疗的需求。拉丁美洲以及中东和非洲地区虽然采用先进疗法的速度较慢，但在感染率上升和加强医疗保健系统的努力的推动下，医疗保健投资不断增加。这些地区正在逐步改善获得创新治疗的机会，创造未来的市场潜力。

艰难梭菌感染治疗市场-竞争格局：

艰难梭菌感染治疗市场竞争激烈，主要参与者专注于合作伙伴关係、收购和药物创新等策略性措施。默克公司和辉凌製药等领先公司处于市场的前沿。默克的 DIFICID(R) (fidaxomicin) 仍然是领先的治疗选择，2022 年，该公司宣布与生物医学高级研究与发展局 (BARDA) 建立合作伙伴关係，探索下一代疗法。 Ferring Pharmaceuticals 因收购Rebiotix, Inc. 而成为头条新闻，加速了其基于微生物组的疗法的开发，其中包括FDA 批准的REBYOTA(R)，这是一种针对CDI 的开创性粪便微生物移植(FMT) 疗法。辉瑞(Pfizer) 也正在取得长足进步，正在研发一种艰难梭菌候选疫苗，该疫苗将于2021 年进入后期临床试验。严重的全球艰难梭菌感染负担，为未来的成长和创新而努力。

最新进展：

2023 年 4 月，Seres Therapeutics 和雀巢健康科学宣布 FDA 批准 VOWST，这是第一个基于口服微生物群的疗法，用于预防成人抗菌治疗后復发性艰难梭菌感染。该产品预计将于六月上市。

2024 年 5 月，Acurx Pharmaceuticals 宣布成功召开了 FDA 伊贝札波尔他 2 期结束会议，确认了治疗艰难梭菌感染的国际 3 期试验计画。 FDA 批准了试验设计和终点，为提交新药申请铺平了道路。

目录

第一章：艰难梭菌感染治疗市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场片段
    • 艰难梭菌感染治疗市场片段（按类型）
    • 依给药途径分類的艰难梭菌感染治疗市场片段
    • 最终使用者的艰难梭菌感染治疗市场片段
    • 艰难梭菌感染治疗市场片段（依国家/地区）
    • 艰难梭菌感染治疗市场片段（按地区）
  • 竞争洞察

第 3 章：艰难梭菌感染治疗主要市场趋势

  • 艰难梭菌感染治疗市场驱动因素
    • 市场驱动因素的影响分析
  • 艰难梭菌感染治疗市场限制
    • 市场限制影响分析
  • 艰难梭菌感染治疗市场机会
  • 艰难梭菌感染治疗市场未来趋势

第 4 章：艰难梭菌感染治疗产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章：艰难梭菌感染治疗市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：艰难梭菌感染治疗市场格局

  • 2023 年艰难梭菌感染治疗市占率分析
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：艰难梭菌感染治疗市场 - 按类型

  • 概述
    • 按类型分類的细分市场占有率分析
    • 抗生素
    • 益生菌
    • 粪便微生物移植（FMT）
    • 单株抗体

第 8 章：艰难梭菌感染治疗市场 - 依给药途径

  • 概述
    • 按给药途径分類的细分市场份额分析
    • 口服
    • 静脉
    • 直肠

第 9 章：艰难梭菌感染治疗市场 - 按最终用户

  • 概述
    • 按最终用户分類的细分市场占有率分析
    • 医院
    • 诊所
    • 长期照护设施
    • 家庭护理设置

第 10 章：艰难梭菌感染治疗市场 - 依地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美艰难梭菌感染治疗主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模和预测（按类型）
    • 北美市场规模与预测（按管理途径）
    • 北美市场规模和预测（按最终用户）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲艰难梭菌感染治疗主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模与预测（按类型）
    • 欧洲市场规模与预测（按管理途径）
    • 欧洲市场规模和预测（按最终用户）
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区艰难梭菌感染治疗主要製造商
    • 亚太地区市场规模与预测（按国家）
    • 亚太地区市场规模与预测（按类型）
    • 亚太地区市场规模与预测（依管理途径）
    • 亚太地区市场规模和预测（按最终用户）
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲艰难梭菌感染治疗主要製造商
    • 拉丁美洲市场规模与预测（按国家）
    • 拉丁美洲市场规模与预测（按类型）
    • 拉丁美洲市场规模与预测（按管理途径）
    • 拉丁美洲市场规模和预测（按最终用户）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲艰难梭菌感染治疗主要製造商
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模及预测（按类型）
    • 中东和非洲市场规模及预测（按管理途径）
    • 中东和非洲市场规模和预测（按最终用户）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 11 章：主要供应商分析 - 艰难梭菌感染治疗产业

  • 竞争仪表板
  • 公司简介
    • Acurx Pharmaceuticals, Inc.
    • Da Volterra
    • Ferring Pharmaceuticals Inc.
    • Finch Therapeutics Group, Inc.
    • Immuron Ltd.
    • Johnson & Johnson Services, Inc.
    • Maat Pharma SA
    • Merck & Co., Inc.
    • Microbiotica Ltd.
    • Pfizer Inc.
    • Prokaryotics Inc.
    • Rebiotix Inc. (a Ferring company)
    • Sanofi SA
    • Seres Therapeutics, Inc.
    • Summit Therapeutics plc
    • Vedanta Biosciences, Inc.
    • Others

第 12 章：360 度分析师视角

第 13 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV3813

REPORT HIGHLIGHT

Clostridium Difficile Infection Treatment Market size was valued at USD 896.90 Million in 2023, expanding at a CAGR of 7.90% from 2024 to 2032.

The Clostridium Difficile Infection (CDI) Treatment Market focuses on therapeutic solutions to combat infections caused by the Clostridium difficile bacterium, which leads to severe diarrhea and inflammation of the colon. The rising incidence of hospital-acquired infections, coupled with the increasing use of broad-spectrum antibiotics, has fueled the demand for effective CDI treatments. Innovative drug developments, such as microbiome therapeutics and monoclonal antibodies, are reshaping the market landscape. Regulatory challenges, particularly in drug approval pathways, act as barriers to market growth. However, with over 450,000 cases of CDI reported annually in the U.S. alone, there is significant opportunity for the development of novel treatment solutions. In addition, the growing awareness of antimicrobial resistance highlights the need for safer and more targeted treatment options, opening avenues for companies to invest in next-generation therapies.

Clostridium Difficile Infection Treatment Market- Market Dynamics

Rising Incidence of Hospital-Acquired Infections Boosts Demand for Clostridium Difficile Infection Treatment Solutions

The increasing prevalence of hospital-acquired infections (HAIs) has intensified the need for effective treatments for Clostridium Difficile infections. According to the Centers for Disease Control and Prevention (CDC), HAIs affect approximately 1 in 31 hospital patients daily, with Clostridium Difficile being one of the most common culprits. In 2020, the CDC reported that C. difficile caused nearly 223,900 infections in hospitalized patients in the U.S. alone, leading to over 12,800 deaths. Efforts by healthcare institutions to reduce HAIs, along with stringent infection control measures, are driving the adoption of more advanced and targeted treatments. With ongoing concerns about antibiotic resistance, the development of alternative therapies, such as fecal microbiota transplants (FMT), has gained momentum as part of a broader strategy to combat these infections.

Clostridium Difficile Infection Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.90% over the forecast period (2024-2032)

Based on Type segmentation, Antibiotics was predicted to show maximum market share in the year 2023

Based on Route of Administration segmentation, Oral was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Clostridium Difficile Infection Treatment Market- Segmentation Analysis:

The Global Clostridium Difficile Infection Treatment Market is segmented on the basis of Type, Route of Administration, End-User, and Region.

The market is divided into four categories based on Type: Antibiotics, Probiotics, Fecal Microbiota Transplantation (FMT), and Monoclonal Antibodies. Antibiotics dominate the Clostridium Difficile Infection Treatment Market due to their widespread use, followed by Fecal Microbiota Transplantation (FMT) gaining momentum as an alternative therapy. Monoclonal antibodies are emerging, while probiotics are seeing increasing attention as supportive treatments.

The market is divided into three categories based on the Route of Administration: Oral, Intravenous, and Rectal. Oral administration is the most common for Clostridium difficile treatments due to ease and patient compliance, followed by intravenous administration, which is used for severe cases. Rectal administration is less common but utilized for targeted therapies like Fecal Microbiota Transplantation (FMT).

Clostridium Difficile Infection Treatment Market- Geographical Insights

The Clostridium Difficile Infection Treatment Market shows significant regional variation, with North America leading due to high infection rates and robust healthcare infrastructure. The CDC estimates that C. difficile causes nearly 12,800 deaths annually in the U.S., making it a critical focus for public health initiatives. Europe follows closely, where the European Centre for Disease Prevention and Control (ECDC) has implemented strict infection control measures, including mandatory reporting of HAIs, which has spurred market growth. The Asia-Pacific region is witnessing rising awareness and improved diagnostic capabilities, particularly in countries like Japan and China. In 2021, Japan's Ministry of Health launched initiatives to reduce antimicrobial resistance, directly impacting the demand for CDI treatments. Latin America and the Middle East & Africa regions, though slower to adopt advanced therapies, are seeing increasing investments in healthcare, driven by rising infection rates and efforts to strengthen healthcare systems. These regions are gradually improving access to innovative treatments, creating future market potential.

Clostridium Difficile Infection Treatment Market- Competitive Landscape:

The Clostridium Difficile Infection Treatment Market is highly competitive, with key players focusing on strategic initiatives such as partnerships, acquisitions, and drug innovation. Leading companies like Merck & Co., Inc. and Ferring Pharmaceuticals are at the forefront of the market. Merck's DIFICID(R) (fidaxomicin) remains a leading treatment option, and in 2022, the company announced a partnership with the Biomedical Advanced Research and Development Authority (BARDA) to explore next-generation therapies. Ferring Pharmaceuticals made headlines with its acquisition of Rebiotix, Inc., accelerating its development of microbiome-based therapies, including the FDA-approved REBYOTA(R), a pioneering fecal microbiota transplant (FMT) therapy for CDI. Pfizer, too, is making strides, working on a C. difficile vaccine candidate that entered late-stage clinical trials in 2021. These strategic moves demonstrate how major players are not only competing but also collaborating to address the growing global burden of CDI, positioning themselves for future growth and innovation.

Recent Developments:

In April 2023, Seres Therapeutics and Nestle Health Science announced FDA approval for VOWST, the first orally administered microbiota-based therapy for preventing recurrent Clostridioides difficile infections in adults after antibacterial treatment. The product is expected to be available in June.

In May 2024, Acurx Pharmaceuticals announced a successful FDA End-of-Phase 2 meeting for ibezapolstat, confirming plans for international Phase 3 trials to treat C. difficile infection. The FDA approved the trial design and endpoints, paving the way for the submission of the New Drug Application.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CLOSTRIDIUM DIFFICILE INFECTION TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Acurx Pharmaceuticals, Inc.
  • Da Volterra
  • Ferring Pharmaceuticals Inc.
  • Finch Therapeutics Group, Inc.
  • Immuron Ltd.
  • Johnson & Johnson Services, Inc.
  • Maat Pharma SA
  • Merck & Co., Inc.
  • Microbiotica Ltd.
  • Pfizer Inc.
  • Prokaryotics Inc.
  • Rebiotix Inc. (a Ferring company)
  • Sanofi S.A.
  • Seres Therapeutics, Inc.
  • Summit Therapeutics plc
  • Vedanta Biosciences, Inc.
  • Others

GLOBAL CLOSTRIDIUM DIFFICILE INFECTION TREATMENT MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Antibiotics
  • Probiotics
  • Fecal Microbiota Transplantation (FMT)
  • Monoclonal Antibodies

GLOBAL CLOSTRIDIUM DIFFICILE INFECTION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Intravenous
  • Rectal

GLOBAL CLOSTRIDIUM DIFFICILE INFECTION TREATMENT MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Clinics
  • Long-Term Care Facilities
  • Homecare Settings

GLOBAL CLOSTRIDIUM DIFFICILE INFECTION TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Clostridium Difficile Infection Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Clostridium Difficile Infection Treatment Market Snippet by Type
    • 2.1.2. Clostridium Difficile Infection Treatment Market Snippet by Route of Administration
    • 2.1.3. Clostridium Difficile Infection Treatment Market Snippet by End-User
    • 2.1.4. Clostridium Difficile Infection Treatment Market Snippet by Country
    • 2.1.5. Clostridium Difficile Infection Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Clostridium Difficile Infection Treatment Key Market Trends

  • 3.1. Clostridium Difficile Infection Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Clostridium Difficile Infection Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Clostridium Difficile Infection Treatment Market Opportunities
  • 3.4. Clostridium Difficile Infection Treatment Market Future Trends

4. Clostridium Difficile Infection Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Clostridium Difficile Infection Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Clostridium Difficile Infection Treatment Market Landscape

  • 6.1. Clostridium Difficile Infection Treatment Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Clostridium Difficile Infection Treatment Market - By Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2023 & 2032 (%)
    • 7.1.2. Antibiotics
    • 7.1.3. Probiotics
    • 7.1.4. Fecal Microbiota Transplantation (FMT)
    • 7.1.5. Monoclonal Antibodies

8. Clostridium Difficile Infection Treatment Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 8.1.2. Oral
    • 8.1.3. Intravenous
    • 8.1.4. Rectal

9. Clostridium Difficile Infection Treatment Market - By End-User

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End-User, 2023 & 2032 (%)
    • 9.1.2. Hospitals
    • 9.1.3. Clinics
    • 9.1.4. Long-Term Care Facilities
    • 9.1.5. Homecare Settings

10. Clostridium Difficile Infection Treatment Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Clostridium Difficile Infection Treatment Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Clostridium Difficile Infection Treatment Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Clostridium Difficile Infection Treatment Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Clostridium Difficile Infection Treatment Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Clostridium Difficile Infection Treatment Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Clostridium Difficile Infection Treatment Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Acurx Pharmaceuticals, Inc.
    • 11.2.2. Da Volterra
    • 11.2.3. Ferring Pharmaceuticals Inc.
    • 11.2.4. Finch Therapeutics Group, Inc.
    • 11.2.5. Immuron Ltd.
    • 11.2.6. Johnson & Johnson Services, Inc.
    • 11.2.7. Maat Pharma SA
    • 11.2.8. Merck & Co., Inc.
    • 11.2.9. Microbiotica Ltd.
    • 11.2.10. Pfizer Inc.
    • 11.2.11. Prokaryotics Inc.
    • 11.2.12. Rebiotix Inc. (a Ferring company)
    • 11.2.13. Sanofi S.A.
    • 11.2.14. Seres Therapeutics, Inc.
    • 11.2.15. Summit Therapeutics plc
    • 11.2.16. Vedanta Biosciences, Inc.
    • 11.2.17. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us